China-U.S. Conference: New Frontiers and Challenges in Antibacterial Resistance (AR) Research

Meeting Summary

Jianguo Garden Hotel Beijing
No. 17 Jianguomennei Avenue, Beijing

The Chinese Academy of Medical Sciences (CAMS) and the United States National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, co-sponsored a workshop on New Frontiers and Challenges in Antibacterial Resistance (AR) Research on September 18 and 19, 2017 in Beijing, China.

Since the discovery of penicillin, antibiotics have been a powerful weapon in the fight against bacterial infections, providing life-saving treatments for more than seven decades. However, excessive and improper use of antibiotics, along with pathogen evolution over time, has created widespread resistance to existing antibiotics, rendering them ineffective for many serious infections. According to the review report Tackling Drug-Resistant Infections Globally, released in May 2016 by the Government of the United Kingdom, antimicrobial resistance (AMR) could lead to 10 million lives lost by 2050. In addition, the economic loss associated with AMR could reach 100 trillion USD cumulatively by 2050 if we do not take action to tackle the problem now. It is clear that each country around the world needs to act together to save future generations from the enormous burden of AMR.  In September 2014, in response to this global crisis, the United States Government published the National Strategy for Combating Antibiotic-Resistant Bacteria (CARB). The resulting National Action Plan on CARB lists five goals, among which are the following: advancing antibiotic research and development, improving international collaboration, and increasing capacity for antibiotic resistance prevention, surveillance and control. 

The United States and China share similar concerns about the impact of antibacterial resistance and the importance of immediately addressing this global public health problem. As the largest US Government funder for research on infectious diseases, NIAID is at the forefront of biomedical research on antibiotic resistance. NIAID supports basic, translational, and clinical research on all aspects of infectious diseases with the ultimate goals of developing better diagnostics, vaccines and treatments. CAMS is the leading institute in China for biomedical research. It has made tremendous investments and progress in recent years in combating the urgent issue of antibacterial resistance in the country. Joining together to discuss research resources and knowledge will synergize US and Chinese efforts in combating antibacterial resistance.

This workshop brought together government representatives, academic researchers, and biomedical companies from both countries to discuss the current state of knowledge, scientific and regulatory challenges, research resources, and potential opportunities for partnerships to advance understanding and the development of new medical countermeasures to address antibacterial resistance. 

Speaker List

Day One: September 18, 2017

Moderators: Emily Erbelding, Jiandong Jiang

  • Qian Liu, Deputy Director of the National Health and Family Planning Commission
  • Gray Handley, NIAID Associate Director for International Research Affairs
  • Jinhui Gu, National Health and Family Planning Commission
  • Lei Wu, National Natural Science Foundation of China
  • Dennis Dixon, NIAID

Session A:  Government actions on Antimicrobial Resistance

  • Moderators: Emily Erbelding, Jiandong Jiang
  • Yohei Doi, University of Pittsburgh, U.S./Global Antibiotic Resistance
  • Minggui Wang, Huashan Hospital, Fudan University, Antibiotic Resistance in China
  • Ed Cox and Sumathi Nambiar, FDA, Regulatory Policies and Process
  • Yanchun Feng, National Institutes for Food and Drug Control, cFDA, Technical Requirements for New Drug
  • Tao Wang, Center for Drug Evaluation, cFDA, Drug Administration Policies

Panel Discussion Q&A

  • Moderators: Dennis Dixon, Minggui Wang

Session B: Antibiotic R&D Programs in China

  • Moderators: Stella Xu, Yinxiang Wang
  • Jiandong Jiang / Xuefu You, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, China Antibiotic R&D Overview
  • Zhi Hong, GSK, China, GSK Perspective on AR
  • Yanchang Wang, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, New TB Drug Discovery
  • Maarten Vercruysse, Roche Shanghai, Roche Perspective on AR
  • Shaojing Hu, Beijing Jiakesi drug development Co., Ltd
  • Daijie Chen, School of Pharmacy, Shanghai Jiao Tong University
  • Yongsheng Che, Beijing Institute of Pharmacology and Toxicology, Plant Derived Compounds for Antibiotics
  • Min Ge, Aisi Medical Technology Limited in Nanjing
  • Tao Zhang, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
  • Microbial Natural Products for Antibiotics
  • Qiwen Yang, Peking Union Medical College Hospital

Day Two: September 19, 2017

Session C: Clinical Trial Capabilities and Network

  • Moderators: Zhenkun Ma, Zhi Hong
  • Vance Fowler, Duke University Medical Center, Antibacterial Resistance Leadership Group Program
  • David van Duin, University of North Carolina, CRACKLE Study
  • Keith Kaye, University of Michigan Medical School, Colistin Study
  • Zhengyu Yuan, MicuRx Pharmaceuticals, Inc. (Shanghai)
  • Zhenkun Ma, TenNor Therapeutics
  • Haihui Huang, Huashan Hospital, Fudan University, Antibiotic Clinical Trials in China
  • Laura Via, NIAID, Experience and Challenges of Doing Clinical Trial in China
  • Yuhong Liu, Beijing Chest Hospital, Capital Medical University, China TB Clinical Trial Consortium

Session D: Collaboration Opportunities

  • Moderators: Joe Larsen, Jiandong Jiang
  • Lanling Zou, NIAID, NIAID Pre-Clinical and Clinical Services
  • Joe Larsen, BARDA, BARDA Programs
  • Sheng Ding, Global Health Drug Discovery Institute, Bill and Melinda Gates Foundation, Foundation’s Vision in Antibiotic R&D in China
  • Vance Fowler, Duke University Medical Center, Training Opportunity through ARLG
  • Mike Mowatt, NIAID, Overview on NIAID Technology Transfer
  • Jiandong Jiang, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Antibiotic R&D in China and Technology Transfer

Closing Remarks

  • Xue Zhang, Chinese Academy of Medical Sciences
  • Dennis Dixon, NIAID
Content last reviewed on